Reglagene is developing novel, orally administered medicines designed to fight life threatening brain cancers known as high-grade glioma. Early testing has shown promise in delivering well-tolerated treatment that can cross the blood-brain barrier to deliver effective treatment that may improve patient prospects.
www.reglagene.com
MILESTONESSeries A-1 |
TARGET CANCERSHigh-Grade Glioma (Brain Cancer) |
FOCUS SECTORTherapies & Management |
WHY WE INVESTED
Since our initial investment in Reglagene’s Series A funding round, we have been impressed by their progress. They completed selection of their lead drug candidate and showed impressive results throughout pre-clinical development. Our Series A-1 investment will help them progress through an Investigational New Drug (IND) Application with the FDA and progress toward human trials. Their team is impressive and, we believe, on track to contribute a new treatment with the potential to improve the quality and length of survivorship for patients with high-grade glioma.
